Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of everolimus combined with metformin in advanced cancer
NL-OMON39171Phase 1Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus and metformin in Nonhematologic neoplasms and cancer, sponsored by Amsterdam University Medical Center. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Started Jan 2013; status: active, not recruiting.
02
Drugs
everolimusmetformin
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON39171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39171.